(COR) Cencora - Ratings and Ratios
Pharmaceuticals, Generics, Vaccines, Plasma, Logistics
Dividends
| Dividend Yield | 0.65% |
| Yield on Cost 5y | 2.45% |
| Yield CAGR 5y | 5.17% |
| Payout Consistency | 90.5% |
| Payout Ratio | 14.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 19.7% |
| Value at Risk 5%th | 29.9% |
| Relative Tail Risk | -7.61% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.79 |
| Alpha | 43.34 |
| CAGR/Max DD | 2.33 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.406 |
| Beta | -0.042 |
| Beta Downside | -0.165 |
| Drawdowns 3y | |
|---|---|
| Max DD | 12.46% |
| Mean DD | 3.57% |
| Median DD | 2.93% |
Description: COR Cencora December 02, 2025
Cencora Inc. (NYSE: COR) is a global pharmaceutical wholesaler that serves a broad spectrum of U.S. and international customers, ranging from acute-care hospitals and retail pharmacies to specialty clinics and animal-health providers. Its U.S. Healthcare Solutions segment handles generic and injectable drugs, over-the-counter products, home-care supplies, plasma and specialty biologics, and offers ancillary services such as pharmacy management, staffing, supply-chain software, packaging, clinical-trial support, and data-analytics for biotech and pharma manufacturers. The International Healthcare Solutions segment extends similar wholesale, distribution, and commercialization capabilities abroad, including specialized logistics for biopharmaceuticals.
Key metrics from the most recent fiscal year (2023) show revenue of roughly $20.9 billion, an operating margin of about 2.5 % and free cash flow of $1.2 billion, reflecting modest profitability typical of the high-volume, low-margin distribution model. Growth is being driven by secular trends such as the aging U.S. population, the accelerating shift toward specialty and biologic therapies, and ongoing consolidation among drug manufacturers that increases reliance on large, integrated distributors. Additionally, Cencora’s investment in supply-chain automation and data-analytics platforms is intended to capture higher-margin services and improve cash-conversion cycles.
For a deeper quantitative view, see ValueRay’s analyst notes on COR.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.55b TTM) > 0 and > 6% of Revenue (6% = 19.28b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -0.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.74% (prev -2.23%; Δ 0.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 3.88b > Net Income 1.55b (YES >=105%, WARN >=100%) |
| Net Debt (3.30b) to EBITDA (3.70b) ratio: 0.89 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (193.9m) change vs 12m ago -2.11% (target <= -2.0% for YES) |
| Gross Margin 3.27% (prev 2.95%; Δ 0.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 447.3% (prev 438.1%; Δ 9.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.82 (EBITDA TTM 3.70b / Interest Expense TTM 388.2m) >= 6 (WARN >= 3) |
Altman Z'' 0.13
| (A) -0.07 = (Total Current Assets 52.24b - Total Current Liabilities 57.82b) / Total Assets 76.59b |
| (B) 0.09 = Retained Earnings (Balance) 6.53b / Total Assets 76.59b |
| (C) 0.04 = EBIT TTM 2.65b / Avg Total Assets 71.85b |
| (D) 0.08 = Book Value of Equity 5.64b / Total Liabilities 74.84b |
| Total Rating: 0.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.41
| 1. Piotroski 5.0pt |
| 2. FCF Yield 4.66% |
| 3. FCF Margin 1.00% |
| 4. Debt/Equity 5.08 |
| 5. Debt/Ebitda 0.89 |
| 6. ROIC - WACC (= 13.12)% |
| 7. RoE 131.5% |
| 8. Rev. Trend 97.01% |
| 9. EPS Trend 82.80% |
What is the price of COR shares?
Over the past week, the price has changed by +1.87%, over one month by -4.64%, over three months by +14.56% and over the past year by +50.21%.
Is COR a buy, sell or hold?
- Strong Buy: 10
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the COR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 384.8 | 11.2% |
| Analysts Target Price | 384.8 | 11.2% |
| ValueRay Target Price | 459.9 | 32.9% |
COR Fundamental Data Overview December 06, 2025
P/E Trailing = 42.3626
P/E Forward = 19.0476
P/S = 0.2038
P/B = 43.1347
P/EG = 0.8936
Beta = 0.633
Revenue TTM = 321.33b USD
EBIT TTM = 2.65b USD
EBITDA TTM = 3.70b USD
Long Term Debt = 7.54b USD (from longTermDebt, last quarter)
Short Term Debt = 117.8m USD (from shortTermDebt, last quarter)
Debt = 7.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.30b USD (from netDebt column, last quarter)
Enterprise Value = 68.80b USD (65.50b + Debt 7.66b - CCE 4.36b)
Interest Coverage Ratio = 6.82 (Ebit TTM 2.65b / Interest Expense TTM 388.2m)
FCF Yield = 4.66% (FCF TTM 3.21b / Enterprise Value 68.80b)
FCF Margin = 1.00% (FCF TTM 3.21b / Revenue TTM 321.33b)
Net Margin = 0.48% (Net Income TTM 1.55b / Revenue TTM 321.33b)
Gross Margin = 3.27% ((Revenue TTM 321.33b - Cost of Revenue TTM 310.84b) / Revenue TTM)
Gross Margin QoQ = 3.53% (prev 3.30%)
Tobins Q-Ratio = 0.90 (Enterprise Value 68.80b / Total Assets 76.59b)
Interest Expense / Debt = 1.02% (Interest Expense 77.8m / Debt 7.66b)
Taxrate = -78.07% (out of range, set to none) (146.0m / -187.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.90 (Total Current Assets 52.24b / Total Current Liabilities 57.82b)
Debt / Equity = 5.08 (Debt 7.66b / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 0.89 (Net Debt 3.30b / EBITDA 3.70b)
Debt / FCF = 1.03 (Net Debt 3.30b / FCF TTM 3.21b)
Total Stockholder Equity = 1.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.03% (Net Income 1.55b / Total Assets 76.59b)
RoE = 131.5% (Net Income TTM 1.55b / Total Stockholder Equity 1.18b)
RoCE = 30.33% (EBIT 2.65b / Capital Employed (Equity 1.18b + L.T.Debt 7.54b))
RoIC = 18.36% (EBIT 2.65b / (Assets 76.59b - Curr.Liab 57.82b - Cash 4.36b))
WACC = 5.25% (E(65.50b)/V(73.16b) * Re(5.86%) + (debt cost/tax rate unavailable))
Discount Rate = 5.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.99%
[DCF Debug] Terminal Value 78.46% ; FCFE base≈3.12b ; Y1≈3.16b ; Y5≈3.43b
Fair Price DCF = 312.2 (DCF Value 60.56b / Shares Outstanding 194.0m; 5y FCF grow 0.81% → 3.0% )
EPS Correlation: 82.80 | EPS CAGR: 11.19% | SUE: 0.43 | # QB: 0
Revenue Correlation: 97.01 | Revenue CAGR: 9.47% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.92 | Chg30d=+0.059 | Revisions Net=+4 | Analysts=14
EPS current Year (2026-09-30): EPS=17.67 | Chg30d=+0.188 | Revisions Net=+11 | Growth EPS=+10.4% | Growth Revenue=+6.0%
EPS next Year (2027-09-30): EPS=19.54 | Chg30d=+0.257 | Revisions Net=+9 | Growth EPS=+10.6% | Growth Revenue=+6.5%
Additional Sources for COR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle